Cato T. Laurencin net worth and biography

Cato Laurencin Biography and Net Worth

Director of Alkermes

Dr. Laurencin is the University Professor and Albert and Wilda Van Dusen Distinguished Endowed Professor of Orthopaedic Surgery at the University of Connecticut (UConn), where he also serves as Professor of Chemical and Biomolecular Engineering, Professor of Materials Science and Engineering and Professor of Biomedical Engineering. He serves as the Chief Executive Officer of the Cato T. Laurencin Institute for Regenerative Engineering. In addition, Dr. Laurencin is a core faculty member of the Africana Studies Institute at UConn, and is the Editor-in-Chief of the Journal of Racial and Ethnic Health Disparities, published by Springer Nature. He co-founded the W. Montague Cobb/NMA Health Institute, which is dedicated to addressing Health Disparities and served as its Founding Chair until 2017. He is currently on the Board of Directors of MiMedx Group, Inc.

What is Cato T. Laurencin's net worth?: The estimated net worth of Cato T. Laurencin is at least $779,680.44 as of December 9th, 2024. Dr. Laurencin owns 23,013 shares of Alkermes stock worth more than $779,680 as of March 25th. This net worth approximation does not reflect any other investments that Dr. Laurencin may own. Learn More about Cato T. Laurencin's net worth.
How do I contact Cato T. Laurencin?: The corporate mailing address for Dr. Laurencin and other Alkermes executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. Alkermes can also be reached via phone at (531) 772-8000 and via email at investor_relations@alkermes.com. Learn More on Cato T. Laurencin's contact information.
Has Cato T. Laurencin been buying or selling shares of Alkermes?: Cato T. Laurencin has not been actively trading shares of Alkermes over the course of the past ninety days. Most recently, Cato T. Laurencin sold 2,691 shares of the business's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $31.85, for a transaction totalling $85,708.35. Following the completion of the sale, the director now directly owns 23,013 shares of the company's stock, valued at $732,964.05. Learn More on Cato T. Laurencin's trading history.
Who are Alkermes' active insiders?: Alkermes' insider roster includes Emily Alva (Director), David Anstice (Director), Iain Brown (CFO), Shane Cooke (Director), Wendy Dixon (Director), David Gaffin (SVP), Craig Hopkinson (EVP), Blair Jackson (COO), Michael Landine (SVP), Cato Laurencin (Director), Christian Nichols (SVP), Richard Pops (Chairman & CEO), and Nancy Wysenski (Director). Learn More on Alkermes' active insiders.
Are insiders buying or selling shares of Alkermes?: During the last year, insiders at the sold shares 8 times. They sold a total of 393,075 shares worth more than $12,938,532.90. The most recent insider tranaction occured on February, 13th when EVP Craig C Hopkinson sold 144,419 shares worth more than $5,131,207.07. Insiders at Alkermes own 4.9% of the company. Learn More about insider trades at Alkermes.
Information on this page was last updated on 2/13/2025.

Cato T. Laurencin Insider Trading History at Alkermes

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/9/2024	Sell	2,691	$31.85	$85,708.35	23,013
6/7/2023	Sell	2,800	$31.50	$88,200.00	7,479

Cato T. Laurencin Buying and Selling Activity at Alkermes

Alkermes Company Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Today's Range

Now: $33.88

$33.71

$34.89

50 Day Range

MA: $33.21

$29.05

$36.00

2 Week Range

Now: $33.88

$22.90

$36.45

Volume

1,407,682 shs

Average Volume

1,696,869 shs

Market Capitalization

$5.51 billion

P/E Ratio

15.61

Dividend Yield

N/A

Beta

0.62